Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozarelix vs Goserelin in Prostate Cancer
NCT01252693Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Nov 2010
- Primary completion
- Sep 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ozarelix in prostate cancer (PCa), sponsored by Spectrum Pharmaceuticals, Inc.. Started Nov 2010; status: completed.
02
Drugs
ozarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01252693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252693.